FLT3 gene mutation – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 28 May 2026 11:30:48 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png FLT3 gene mutation – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Study of Gilteritinib to Eliminate Remaining Cancer Cells in Patients with Acute Myeloid Leukemia and FLT3-ITD Mutation https://clinicaltrials.eu/trial/a-study-of-gilteritinib-to-eliminate-remaining-cancer-cells-in-patients-with-acute-myeloid-leukemia-and-flt3-itd-mutation/ Wed, 29 Apr 2026 15:07:55 +0000 https://clinicaltrials.eu/trial/a-study-of-gilteritinib-to-eliminate-remaining-cancer-cells-in-patients-with-acute-myeloid-leukemia-and-flt3-itd-mutation/ This study involves patients with acute myeloid leukemia, a type of blood cancer that affects the bone marrow and blood cells. Specifically, the study focuses on patients whose cancer cells have a particular genetic change called FLT3-ITD mutation, which means the cancer cells have an abnormal version of a specific gene. The treatment being tested is gilteritinib, which is also known by its brand name Xospata. This medication belongs to a group of drugs called tyrosine kinase inhibitors, which work by blocking certain proteins that help cancer cells grow and survive. The study will look at patients who still have small amounts of cancer cells remaining in their body, called measurable residual disease, even after they have already received two rounds of intensive chemotherapy combined with another similar medication.

The purpose of the study is to see how well gilteritinib works at eliminating these remaining cancer cells that can be detected using a special laboratory test called PCR-NGS. During the study, patients will receive gilteritinib tablets by mouth for up to eight months. The medication will be given at a dose of up to 120 milligrams per day. Throughout the treatment period, doctors will monitor patients regularly to check if the remaining cancer cells have disappeared and to observe how patients respond to the medication.

The study will also examine several additional aspects, including what types of genetic changes might appear if the cancer comes back, how long the treatment works before any resistance develops, and whether certain characteristics of the cancer cells or the patient’s immune system can predict how well the treatment will work. Doctors will use various laboratory tests to analyze changes in cancer cells and to look for specific genetic markers that might be related to treatment response. The study will also investigate whether certain mutations present alongside the FLT3-ITD mutation, such as those in genes called DNMT3A, NPM1, TET2, ASXL1, and TP53, have any effect on how patients respond to treatment.

]]>